Home / HealthNews / Indivior legal costs rise, new anti-addiction drug ready

Indivior legal costs rise, new anti-addiction drug ready

LONDON (Reuters) – Britain’s Indivior, which makes drugs to treat opioid addiction and plans to launch a key new product this month, said on Thursday it had increased provisions for investigative and antitrust litigation matters to $438 million.

The U.S. Department of Justice is probing its marketing practices. The company also faces claims it tried to delay entry of generic versions of some of its products.

Analysts at brokerage Jefferies said the $185 million increase in legal provisions in the fourth quarter of 2017 was “sizeable” but could signal Indivior was making progress in settling the issues, which would be positive.

Indivior said it would launch its new once-monthly anti-addiction injection Sublocade in the United States in the week of Feb. 26.

The company expects group sales of between $1.13 and $1.17 billion in 2018, up from $1.09 billion last year.

Reporting by Ben Hirschler; Editing by David Holmes

About admin

Check Also

Frail elderly face increased risk of delirium after surgery

(Reuters Health) – Older adults who have elective surgery are more likely to experience delirium …

Leave a Reply

Your email address will not be published. Required fields are marked *